16 2023.02

RemeGen Disitamab Vedotin in Combination with Pyrotinib Maleate Tablets in the Treatment of Non-Small Cell Lung Cancer Approved for Clinical Trials

20 2022.12

RemeGen RC118 phase I clinical study shows favorable safety and tolerability

17 2022.10

RemeGen receives approval to conduct a global multicenter phase 3 clinical trial of Telitacicept for SLE in the European Union and China

12 2022.10

RemeGen gains FDA’s Orphan Drug designation for Telitacicept in myasthenia gravis

04 2022.06

Disitamab Vedotin appeared on ASCO 2022 meeting and brought exciting clinical data on urothelial carcinoma

09 2022.05

New clinical data of Telitacicept was published in Lupus, for the indication of children's systemic lupus erythematosus (cSLE)

31 2022.03

RemeGen has successfully completed A-share listing IPO, starting a new era of “A+H”

18 2022.02

RC48-ADC appeared on ASCO-GU 2022 meeting and the ORR of HER2(3+) patients reached 100%

03 2021.12

Telitacicept and Disitamab Vedotin have been included in the National Reimbursement Drug List (NRDL)

01 2021.12

First patient enrolled in RC118 phaseⅠclinical trial in Australia by RemeGen! RC118, an ADC drug targeting Claudin18.2